| 產品名稱 |
UACC-3199 |
| 商品貨號 |
B178036 |
| Organism |
Homo sapiens, human |
| Tissue |
mammary gland/breast duct; derived from metastatic site: axillary lymph node |
| Product Format |
frozen |
| Morphology |
epithelial-like |
| Culture Properties |
adherent |
| Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease |
infiltrating ductal carcinoma of the breast |
| Age |
58 years old |
| Gender |
female |
| Ethnicity |
Caucasian |
| Applications |
This cell line is an excellent tool for research into aberrant cytosine methylation of CpG island sites and BRCA1 repression in sporadic breast cancer. It is also very useful as a methylated BRCA1 control. |
| Storage Conditions |
liquid nitrogen vapor phase |
| Images |
 |
| Derivation |
UACC-3199 was derived from a 58 year-old female with infiltrating ductal carcinoma of the breast metastatic to the left axillary lymph nodes. |
| Clinical Data |
female
The patient had a family history of breast cancer.
58 years old
Caucasian |
| Receptor Expression |
epidermal growth factor receptor (EGF), expressed estrogen receptor, not expressed progesterone receptor, not expressed |
| Oncogene |
c-erbB-2 positive |
| Genes Expressed |
c-erbB-2 positive |
| Tumorigenic |
YES |
| Comments |
The patient had a family history of breast cancer. |
| Complete Growth Medium |
The base medium for this cell line is ATCC-formulated Leibovitz's L-15 Medium (ATCC® 30-2008). To make the complete growth medium, add the following components to the base medium:
- fetal bovine serum to a final concentration of 5%
- 0.01 mg/mL transferrin (final conc.)
- 0.01 mg/mL insulin (final conc.)
- 5 µg/mL (55 U/mL) catalase (final conc.)
- 3.6 µg/mL (0.01 mM) hydrocortisone (final conc.)
- extra 2 mM glutamine
|
| Subculturing |
Volumes used in this protocol are for 75 cm 2 flasks; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes.
- Remove and discard culture medium.
- Briefly rinse the cell layer with Ca++/Mg++ free Dulbecco's phosphate-buffered saline (D-PBS) or 0.25% (w/v) Trypsin - 0.53 mM EDTA solution to remove all traces of serum which contains trypsin inhibitor.
- Add 1.0 to 2.0 mL of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
- Add 6.0 to 8.0 mL of complete growth medium and aspirate cells by gently pipetting.
- Transfer cell suspension to a centrifuge tube and spin at approximately 125 x g for 5 to 10 minutes. Discard supernatant.
- Resuspend the cell pellet in fresh growth medium. Add appropriate aliquots of the cell suspension to new culture vessels. An inoculum of 1 X 104 to 2 X 104 viable cells/cm2 is recommended.
- Incubate cultures at 37°C. Subculture when the cell concentration is between 2 X 104 to 5 X 104 cells/cm2.
Subcultivation ratio: A subcultivation ratio of 1:2 to 1:3 is recommended
Medium renewal: Every 3 to 4 days
Growth Conditions: Cells grow very slowly. Cultures reach confluence in 2 to 3 weeks. Avoid inoculating vessels below recommended seeding density. |
| Cryopreservation |
Freeze medium: complete growth medium, 90%; DMSO, 10% Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions |
Temperature: 37°C
Atmosphere: air, 100% |
| STR Profile |
CSF1PO: 12 D13S317: 11 D16S539: 12 D5S818: 13 D7S820: 10 THO1: 9.3 TPOX: 10, 13 vWA: 15, 17 Amelogenin: X |
| Name of Depositor |
K Brown |
| Year of Origin |
November 1994 |
| References |
Rice JC, et al. Transcriptional repression of BRCA1 by aberrant cytosine methylation, histone hypoacetylation and chromatin condensation of the BRCA1 promoter. Nucleic Acids Res. 28(17): 3233-3239, 2000. PubMed: 10954590
Rice JC, et al. Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells. Oncogene 17(14): 1807-1812, 1998. PubMed: 9778046
|